undamentalytics Newsletter
Sign in

Evolus, Inc. balance sheet

At the end of fiscal 2025, Evolus, Inc. had total assets of $226m, total liabilities of $249m and shareholders' equity of −$23.1m. It held $53.8m in cash against $150m of debt: net debt of $96.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents931101031465463875445
Receivables01110152231485562
Inventory06321911122741
Total current assets94152128179101112151143168
Goodwill212121212121212121
Total assets172240209257178189233226248
Accounts payable261069492344
Deferred revenue (current)—238911141212
Total current liabilities524180584748637599
Long-term debt074417172120122146157
Total debt1775417575125125150160
Total liabilities87161282176159210227249279
Shareholders' equity8479−738218−216−23−31
Net debt (negative = net cash)−76−35−62−7121623896115
Shares outstanding27m34m34m56m56m58m63m65m66m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EOLS vs XERSEOLS vs HROWEOLS vs IRWD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Evolus, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evolus, Inc.